Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 13/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63813 | 0.85 | CYP2C9 (0.40) | CYP2C9KCNH2SLC22A2CYP3A4TMEM97 | |
| SCHEMBL63387 | 0.84 | CYP2C9 (0.41) | CYP2C9KCNH2SLC22A2CYP3A4TMEM97 | |
| SCHEMBL62967 | 0.83 | CYP2C9 (0.44) | CYP2C9KCNH2SLC22A2CYP3A4TMEM97 | |
| SCHEMBL62962 | 0.81 | KCNH2 (0.55) | CYP2C9KCNH2 | |
| SCHEMBL13917344 | 0.79 | CYP2C9 (0.42) | CYP2C9KCNH2HCRTR1SLC22A2CYP3A4 | |
| SCHEMBL2965986 | 0.78 | CYP2C9 (0.38) | CYP2C9KCNH2HCRTR1SLC22A2CYP3A4 | |
| SCHEMBL4399776 | 0.78 | CYP2C9 (0.40) | CYP2C9KCNH2HCRTR1SLC22A2MGLL | |
| SCHEMBL2960284 | 0.77 | CYP2C9 (0.37) | CYP2C9KCNH2HCRTR1SLC22A2CYP3A4 | |
| SCHEMBL1379630 | 0.77 | CYP2C9 (0.41) | CYP2C9KCNH2HCRTR1CYP3A4F2 | |
| SCHEMBL3841171 | 0.76 | CYP2C9 (0.37) | CYP2C9KCNH2HCRTR1CYP3A4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CYP2C9 602/4885KCNH2 3969/4885HCRTR1 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.